Exactly right—some of the buyout money from the large mergers will be recycled into other drug/biotech companies, which helps to solidify the companies whose stocks are recipients of this money and thereby facilitates capital-raising and funding of new R&D by these companies.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”